Product
IBI322
4 clinical trials
4 indications
Indication
Advanced MalignanciesIndication
Advanced Solid TumorIndication
Myeloid TumorIndication
Advanced Malignant Tumors LymphomasClinical trial
A Phase 1a/1b Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Advanced Malignant TumorsStatus: Completed, Estimated PCD: 2023-08-28
Clinical trial
A Phase 1a/1b Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors.Status: Completed, Estimated PCD: 2022-12-03
Clinical trial
A Phase Ia/Ib Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid TumorStatus: Terminated, Estimated PCD: 2023-06-19
Clinical trial
A Phase 1a Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Advanced Malignant TumorsStatus: Completed, Estimated PCD: 2023-02-28